Back to Search
Start Over
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- Source :
- Immunotherapy. 8:449-460
- Publication Year :
- 2016
- Publisher :
- Future Medicine Ltd, 2016.
-
Abstract
- Mesothelin is a promising target for immune-based therapy, specifically for mesothelioma and pancreatic and ovarian cancers that have high levels of mesothelin expression. Many preclinical and clinical studies that target tumors with high mesothelin expression with antibodies, immunotoxins, antibody–drug conjugates and vaccines have shown the potential of mesothelin as a target. Studies of T cells genetically modified with chimeric antigen receptors (CAR) report significant efficacy in hematologic malignancies, and antimesothelin CAR T cells are currently being investigated in clinical studies. Here we outline the rationale for using mesothelin as a target for immunotherapy, review the clinical and preclinical studies evaluating mesothelin-directed therapies and explore the promise of CAR T cells directed against mesothelin for immunotherapy in the future.
- Subjects :
- Mesothelioma
0301 basic medicine
endocrine system diseases
Recombinant Fusion Proteins
T-Lymphocytes
medicine.medical_treatment
Immunology
Receptors, Antigen, T-Cell
Review
GPI-Linked Proteins
Cancer Vaccines
Immunotherapy, Adoptive
03 medical and health sciences
0302 clinical medicine
Immune system
Immunotoxin
Pancreatic cancer
medicine
Animals
Humans
Immunology and Allergy
Mesothelin
Molecular Targeted Therapy
Ovarian Neoplasms
Clinical Trials as Topic
biology
business.industry
Immunotherapy
medicine.disease
Chimeric antigen receptor
Pancreatic Neoplasms
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
biology.protein
Female
Antibody
Ovarian cancer
business
Subjects
Details
- ISSN :
- 17507448 and 1750743X
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Immunotherapy
- Accession number :
- edsair.doi.dedup.....cf1ff47f6b77d91b3ea9b2cb76a32cc6
- Full Text :
- https://doi.org/10.2217/imt.16.4